1 citations
,
February 1971 in “JAMA” Triamcinolone acetonide helps scalp grafts grow hair successfully.
50 citations
,
June 1999 in “Annals of Oncology” Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.
24 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Adalimumab improved folliculitis decalvans in most patients.
16 citations
,
March 2020 in “Journal of The American Academy of Dermatology” Oral bicalutamide is safe and effective for female hair loss.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
March 2025 in “International Journal of Trichology” Low-dose oral minoxidil is safe for the heart.
April 2023 in “Tikrit Journal of Pharmaceutical Sciences” Deferasirox effectively reduces iron overload in ß-thalassemia patients but may cause some manageable side effects.
January 2010 in “Chinese Medical Journal of Metallurgical Industry” Leflunomide with prednisone is effective and well-tolerated for lupus nephritis when cyclophosphamide can't be used.
August 2022 in “International Journal of Dermatology” Low-dose oral and sublingual minoxidil seem safe for children with hair disorders.
12 citations
,
June 2019 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Proper skin toxicity management in chemotherapy is key to continuing treatment and keeping patient quality of life high.
16 citations
,
January 2017 in “Archives of Medical Science” Sorafenib after liver surgery may increase survival for some liver cancer patients.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
October 2018 in “The American Journal of Gastroenterology” Late dumping syndrome after fundoplication can be diagnosed with an oral glucose tolerance test and managed with diet changes.
Baricitinib shows promise for treating alopecia areata with mild side effects.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
505 citations
,
October 2011 in “Journal of clinical oncology” MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
30 citations
,
August 2009 in “Journal of the American Academy of Dermatology” Bimatoprost is safe but not effective for severe eyelash loss from alopecia areata, possibly helping those with less loss.
21 citations
,
October 2023 in “Journal of Dermatological Treatment” Baricitinib effectively reduces hair loss in severe alopecia areata and is generally safe.
8 citations
,
June 2022 in “Frontiers in Medicine” Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
5 citations
,
May 2024 in “Journal of Allergy and Clinical Immunology Global” Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
3 citations
,
June 2019 in “Dermatologic Therapy” Biofibre hair implant is a safe, effective treatment for baldness with 95% patient satisfaction.
1 citations
,
July 2024 in “JAAD Case Reports” Gabapentin may help relieve itchy scalp in lichen planopilaris patients.
The treatment showed limited success in repigmenting hair for vitiligo-associated leukotrichia.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.